Hot Topics: Testicular Cancer - Improving Survivorship and Survival

Friday, October 31, 2025

15:15 - 16:45 GMT+0

Co-Chair(s)

Scott Gilbert

Senior Member and Professor, Department of GU Oncology
Moffitt Cancer Center, United States

At the end of this session, attendees should be able to:

Examine the current landscape of biomarker development and their clinical utility for early diagnosis and surveillance of testicular cancer.
Recall management strategies for stage I and II seminoma and non-seminomatous germ cell tumors (NSGCT).
Examine the benefits, limitations, and technical considerations of robotic retroperitoneal lymph node dissection (RPLND) in testicular cancer treatment.
Explore strategies for mitigating treatment-related toxicities and optimizing outcomes through multidisciplinary patient-centered approaches.

15:15 - 15:25 GMT+0

Advancements in Biomarkers for Early Detection and Monitoring: Where Are We Now?
Speaker: Siamak Daneshmand – University of Southern California
15:25 - 15:35 GMT+0

Management of Stage I Seminoma/NSGCT: Optimizing Psychosocial and Gonadal Outcomes
Speaker: Scott Gilbert – Moffitt Cancer Center
15:35 - 15:45 GMT+0

Management of Stage II Seminoma: Where Are We Now?
Speaker: Siamak Daneshmand – University of Southern California
15:45 - 15:55 GMT+0

Robotic RPLND: Progress and Pitfalls
Speaker: Reza Mehrazin – Mount Sinai Hospital New York
15:55 - 16:05 GMT+0

Long-Term Survivorship: Managing Treatment Related Toxicity
16:05 - 16:15 GMT+0

Importance of Multi-Disciplinary Approaches in Managing Testicular Cancer
Speaker: Brusabhanu Nayak, MS, MCh – All India Institute of Medical Sciences
16:15 - 16:25 GMT+0

Primum Non Nocere: The Barts Experience
Speaker: Tim Oliver, MD – Queen Mary University of London
16:25 - 16:45 GMT+0

Case-Based Management of Stage II NSGCT: Perfecting Outcomes
Speaker: Mahendra Pal – Tata Memorial Hospital, Homi Bhabha National Institute